CIBC Asset Management Inc Acquires Shares of 1,875 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CIBC Asset Management Inc bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 1,875 shares of the specialty pharmaceutical company’s stock, valued at approximately $209,000.

Other institutional investors have also modified their holdings of the company. Kovack Advisors Inc. increased its holdings in Jazz Pharmaceuticals by 20.4% during the 3rd quarter. Kovack Advisors Inc. now owns 57,672 shares of the specialty pharmaceutical company’s stock worth $6,425,000 after purchasing an additional 9,783 shares during the last quarter. MQS Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the third quarter worth $253,000. Victory Capital Management Inc. raised its holdings in Jazz Pharmaceuticals by 23.3% in the third quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock valued at $28,220,000 after acquiring an additional 47,807 shares in the last quarter. American Assets Inc. bought a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $557,000. Finally, Venturi Wealth Management LLC grew its holdings in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,110 shares of company stock valued at $720,160. Insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on JAZZ shares. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. TD Cowen reduced their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Wells Fargo & Company lowered their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $175.33.

Jazz Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ:JAZZ opened at $126.67 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company’s 50-day moving average price is $113.29 and its 200 day moving average price is $110.62. The company has a market cap of $7.66 billion, a PE ratio of 17.62, a P/E/G ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.